Both extracellular vesicles (EVs) and long noncoding RNAs (lncRNAs) have been increasingly investigated as biomarkers, pathophysiological mediators, and potential therapeutics. While these two entities have often been studied separately, there are increasing reports of EV-associated lncRNA activity in processes such as oncogenesis as well as tissue repair and regeneration. Given the powerful nature and emerging translational impact of other noncoding RNAs such as microRNA (miRNA) and small interfering RNA, lncRNA therapeutics may represent a new frontier. While EVs are natural vehicles that transport and protect lncRNAs physiologically, they can also be engineered for enhanced cargo loading and therapeutic properties. In this review, we will summarize the activity of lncRNAs relevant to both tissue repair and cancer treatment and discuss the role of EVs in enabling the potential of lncRNA therapeutics. K E Y W O R D S exosomes, extracellular vesicles, lncRNA, microparticles, microvesicles lncRNAs play diverse regulatory roles in normal physiological processes. Thus, delivery of lncRNAs via EVs may help in the treatment Abbreviations: CRCs, colorectal carcinoma cells; EVs, extracellular vesicles; hAD-MSCs, human adipose-derived mesenchymal stem cells; HCAECs, human coronary artery endothelial cells; HCC, hepatocellular carcinoma cell; HDFs, human dermal fibroblasts; HDMECs, human dermal microvascular endothelial cells; lncRNA, long noncoding RNA; miRNA, microRNA; SCCs, squamous carcinoma cells.